Page 1 | Search Results | Blood | American Society of Hematology

1-10 of 10

Sort by

Sort Order Select

Journal Articles

Germline POT1 Variants Can Predispose to a Variety of Hematologic Neoplasms

Tristan L. Lim, BSc, David B. Lieberman, MS, CGC, Adam R. Davis, MD, Ryan Hausler, MS, Ashkan Bigdeli, MS, Yimei Li, PhD, Jacquelyn Powers, MS, LCGC, Regeneron Genetics Center, Shannon A. Carty, MD, Katherine L. Nathanson, MD, Adam Bagg, MD, Elizabeth O. Hexner, MD MSTR, Kara N. Maxwell, MD PhD, Jennifer J.D. Morrissette, PhD, Daria V. Babushok, MD PhD

Blood (2020) 136 (Supplement 1): 2–4.

https://doi.org/10.1182/blood-2020-134160

Published: 2020

Journal Articles

Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC Rearrangement

Zachary AK Frosch, MD, Sunita Dwivedy Nasta, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Elise A. Chong, MD, Emily C. Ayers, MD, Joanna M Rhodes, MD, Alexa Koike, Jennifer J.D. Morrissette, PhD, Daniel J. Landsburg, MD

Blood (2019) 134 (Supplement_1): 1607.

https://doi.org/10.1182/blood-2019-125944

Published: 2019

Journal Articles

Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing

Benjamin M Manning, MD PhD, Robyn T Sussman, PhD, Safoora Deihimi, Noelle V. Frey, MD, Elizabeth O. Hexner, MD MS, Alison W. Loren, MD MS, Selina Luger, MD, James K. Mangan, MD PhD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Jennifer J.D. Morrissette, PhD, Alexander E. Perl, MD, Edward A. Stadtmauer, MD FACP, David L. Porter, MD, Saar I. Gill, MD PhD

Blood (2018) 132 (Supplement 1): 2134.

https://doi.org/10.1182/blood-2018-99-117410

Published: 2018

Journal Articles

Limited FISH Testing for MDS-Defining Cytogenetic Abnormalities Rapidly Identifies Patients with Newly Diagnosed AML Eligible for CPX-351

Christine M. McMahon, MD, Nya Nelson, MD PhD, Alex Ganetsky, PharmD, James K. Mangan, MD PhD, Noelle V. Frey, MD, Alexander E. Perl, MD, Mary Ellen Martin, MD, Shannon R. McCurdy, MD, Alison W. Loren, MD MS, Elizabeth O. Hexner, MD MS, Adam Bagg, MD, Jennifer J.D. Morrissette, PhD, Selina Luger, MD

Blood (2018) 132 (Supplement 1): 4785.

https://doi.org/10.1182/blood-2018-99-116415

Published: 2018

Journal Articles

Clinical Evidence That Deficiency of the Methylcytosine Dioxygenase TET2 Gene Promotes the Clonal Expansion and Therapeutic Efficacy of CD19-Directed T Cells

Blood (2017) 130 (Supplement 1): 1909.

https://doi.org/10.1182/blood.V130.Suppl_1.1909.1909

Published: 2017

Journal Articles

Interim PET-CT Result Is Not Predictive of Survival in Patients with MYC -Rearranged Non-Burkitt Aggressive B Cell Lymphoma

Hua-Jay J. Cherng, MD, Rachel Lynn Sargent, MD, Sunita Dwivedy Nasta, MD, Jakub Svoboda, MD, Stephen J. Schuster, MD, Anthony R. Mato, MD, April Schrank-Hacker, Jennifer J.D. Morrissette, PhD, Daniel J. Landsburg, MD

Blood (2017) 130 (Supplement 1): 4136.

https://doi.org/10.1182/blood.V130.Suppl_1.4136.4136

Published: 2017

Journal Articles

Mechanisms of Acquired Resistance to Gilteritinib Therapy in Relapsed and Refractory FLT3 -Mutated Acute Myeloid Leukemia

Christine M. McMahon, MD, Jonathan Canaani, MD, Bryan Rea, MD, Rachel Lynn Sargent, MD, Jennifer J.D. Morrissette, PhD, David B. Lieberman, MS, CGC, Christopher Watt, MD PhD, Gregory W. Schwartz, PhD, Robert B. Faryabi, PhD, Timothy T. Ferng, MD, Neil P. Shah, MD PhD, Catherine C. Smith, MD, Martin Carroll, MD, Alexander E. Perl, MD

Blood (2017) 130 (Supplement 1): 295.

https://doi.org/10.1182/blood.V130.Suppl_1.295.295

Published: 2017

Journal Articles

Mutational Shift in FLT3 and NPM1-Positive Acute Myeloid Leukemia (AML) Relative to Therapy and Disease Progression

Priya D Velu, MD PhD, Chris C.S. Hsiung, PhD, Kiarash Salafian, Adam Bagg, MD, Jennifer J.D. Morrissette, PhD, Selina Luger, MD

Blood (2016) 128 (22): 2866.

https://doi.org/10.1182/blood.V128.22.2866.2866

Published: 2016

Journal Articles

Utilization of Next Generation Sequencing Identifies Potentially Actionable Mutations with Prognostic Significance in Chronic Lymphocytic Leukemia

Jie Wang, MD, Jennifer J.D. Morrissette, PhD, E. Paul Wileyto, PhD, Stephen J. Schuster, MD, Alexandra Vandegrift, BA, Allison Rago, BSN, Colleen Dorsey, BSN, David Porter, MD, Daniel J. Landsburg, MD, Prioty Islam, MD, Sunita Dwivedy Nasta, MD, Jakub Svoboda, MD, Alison Loren, MD MS, Scott Weber, BS, Edward A. Stadtmauer, MD, Anthony Mato, MD

Blood (2015) 126 (23): 2929.

https://doi.org/10.1182/blood.V126.23.2929.2929

Published: 2015

Journal Articles

Patients with "Single-Hit" but Not MYC -Amplified Non-Burkitt High-Grade B Cell Non-Hodgkin Lymphomas Experience Poor Survival Outcomes and May Benefit from Intensive Induction Therapy

Daniel J. Landsburg, MD, Marissa K. Falkiewicz, Jennifer J.D. Morrissette, PhD, April M. Schrank-Hacker, Sunita Dwivedy Nasta, MD, Jakub Svoboda, MD, Stephen J. Schuster, MD, Anthony R. Mato, MD, Benjamin A. Chu, Yanming Zhang, MD, Amir Behdad, MD, Adam M. Petrich, MD

Blood (2015) 126 (23): 2696.

https://doi.org/10.1182/blood.V126.23.2696.2696

Published: 2015

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Germline POT1 Variants Can Predispose to a Variety of Hematologic Neoplasms

Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC Rearrangement

Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing

Limited FISH Testing for MDS-Defining Cytogenetic Abnormalities Rapidly Identifies Patients with Newly Diagnosed AML Eligible for CPX-351

Clinical Evidence That Deficiency of the Methylcytosine Dioxygenase TET2 Gene Promotes the Clonal Expansion and Therapeutic Efficacy of CD19-Directed T Cells

Interim PET-CT Result Is Not Predictive of Survival in Patients with MYC -Rearranged Non-Burkitt Aggressive B Cell Lymphoma

Mechanisms of Acquired Resistance to Gilteritinib Therapy in Relapsed and Refractory FLT3 -Mutated Acute Myeloid Leukemia

Mutational Shift in FLT3 and NPM1-Positive Acute Myeloid Leukemia (AML) Relative to Therapy and Disease Progression

Utilization of Next Generation Sequencing Identifies Potentially Actionable Mutations with Prognostic Significance in Chronic Lymphocytic Leukemia

Patients with "Single-Hit" but Not MYC -Amplified Non-Burkitt High-Grade B Cell Non-Hodgkin Lymphomas Experience Poor Survival Outcomes and May Benefit from Intensive Induction Therapy

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only